DBV Stock Chart & Stats
€3.64
€0.06(9.51%)
At close: 4:00 PM EST
€3.64
€0.06(9.51%)
Day’s Range― - ―
52-Week Range€1.41 - €4.50
Previous CloseN/A
Volume0.00
Average Volume (3M)4.25K
Market Cap
€724.84M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta-0.97
Next Earnings
Oct 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding314,388,800
10 Day Avg. Volume5,894
30 Day Avg. Volume4,245
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.59M
Bulls Say, Bears Say
Bulls Say
Focused EPIT PlatformDBV has a clearly defined technology platform and lead development program focused on food allergy treatment. This specialization can support concentrated scientific execution and potential platform value if Viaskin Peanut advances successfully through development and regulatory review.
Low Leverage Balance SheetLow debt relative to equity reduces solvency pressure compared with more leveraged biotechnology companies and preserves some financial flexibility. The equity-supported asset base provides a stronger balance-sheet foundation while DBV continues developing its clinical pipeline.
Stable Net Loss TrendA lack of meaningful deterioration in net losses suggests that the company’s expense burden has not accelerated further over the latest comparison period. While profitability remains weak, relative stability can improve planning visibility as DBV advances its development programs.
Bears Say
No Commercial Product RevenueDBV lacks an established commercial revenue base, so its ability to fund operations depends on clinical progress, regulatory approval, and eventual commercialization. This makes future revenue highly uncertain and leaves the business without recurring product sales to absorb development costs.
Large Ongoing Operating LossesThe scale of operating and net losses shows that DBV is far from self-sustaining and has not yet demonstrated operating leverage. Persistently negative profitability can consume shareholder capital and will require successful development outcomes before earnings can become durable.
Severe Cash BurnHeavy negative operating and free cash flow indicates substantial funding needs to maintain the company’s activities. Continued cash consumption increases reliance on external financing and can constrain strategic flexibility if development spending remains high without commercial cash inflows.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.41 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €724.84M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 50 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,388,800 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -6.264%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in DE:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.